Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI

This prospective multicenter study demonstrates that hepatobiliary hyperintensity on Gd-EOB-DTPA-enhanced MRI-an imaging surrogate of Wnt/β-catenin activation-does not indicate resistance to atezolizumab plus bevacizumab. These findings support the use of combination immunotherapy in molecularly "immune-cold" HCC.